% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gnter:292063,
      author       = {M. Günter$^*$ and K. A. L. Mueller and M. J. Salazar$^*$
                      and S. Gekeler and C. Prang and T. Harm and M. P. Gawaz and
                      S. Autenrieth$^*$},
      title        = {{I}mmune signature of patients with cardiovascular disease
                      predicts increased risk for a severe course of {COVID}-19.},
      journal      = {European journal of immunology},
      volume       = {54},
      number       = {11},
      issn         = {0014-2980},
      address      = {Weinheim},
      publisher    = {Wiley-VCH},
      reportid     = {DKFZ-2024-01571},
      pages        = {e2451145},
      year         = {2024},
      note         = {#EA:D431#LA:D431# / 2024 Nov;54(11):e2451145},
      abstract     = {Severe acute respiratory syndrome coronavirus type 2
                      (SARS-CoV-2) infection can lead to life-threatening clinical
                      manifestations. Patients with cardiovascular disease (CVD)
                      are at higher risk for severe courses of COVID-19. So far,
                      however, there are hardly any strategies for predicting the
                      course of SARS-CoV-2 infection in CVD patients at hospital
                      admission. Thus, we investigated whether this prediction is
                      achievable by prospectively analysing the blood
                      immunophenotype of 94 nonvaccinated participants, including
                      uninfected and acutely SARS-CoV-2-infected CVD patients and
                      healthy donors, using a 36-colour spectral flow cytometry
                      panel. Unsupervised data analysis revealed little
                      differences between healthy donors and CVD patients, whereas
                      the distribution of the cell populations changed
                      dramatically in SARS-CoV-2-infected CVD patients. The latter
                      had more mature NK cells, activated monocyte subsets,
                      central memory CD4+ T cells, and plasmablasts but fewer
                      dendritic cells, CD16+ monocytes, innate lymphoid cells, and
                      CD8+ T-cell subsets. Moreover, we identified an immune
                      signature characterised by CD161+ T cells, intermediate
                      effector CD8+ T cells, and natural killer T (NKT) cells that
                      is predictive for CVD patients with a severe course of
                      COVID-19. Thus, intensified immunophenotype analyses can
                      help identify patients at risk of severe COVID-19 at
                      hospital admission, improving clinical outcomes through
                      specific treatment.},
      keywords     = {Cardiovascular disease (Other) / Immune signature (Other) /
                      Immuno‐response (Other) / SARS‐CoV‐2 infection (Other)
                      / Spectral flow cytometry (Other)},
      cin          = {D431},
      ddc          = {610},
      cid          = {I:(DE-He78)D431-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39094122},
      doi          = {10.1002/eji.202451145},
      url          = {https://inrepo02.dkfz.de/record/292063},
}